BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 11486167)

  • 1. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
    Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
    Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.
    Umbas R; Schalken JA; Aalders TW; Carter BS; Karthaus HF; Schaafsma HE; Debruyne FM; Isaacs WB
    Cancer Res; 1992 Sep; 52(18):5104-9. PubMed ID: 1516067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
    J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes.
    Ray ME; Mehra R; Sandler HM; Daignault S; Shah RB
    J Urol; 2006 Oct; 176(4 Pt 1):1409-14; discussion 1414. PubMed ID: 16952645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
    Jaggi M; Johansson SL; Baker JJ; Smith LM; Galich A; Balaji KC
    Urol Oncol; 2005; 23(6):402-6. PubMed ID: 16301117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
    Imasato Y; Xuan JW; Sakai H; Izawa JI; Saito Y; Chin JL; Moussa M
    J Urol; 2000 Nov; 164(5):1819-24. PubMed ID: 11025776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer.
    Musiał J; Sporny S; Nowicki A
    Pol J Pathol; 2007; 58(4):235-43. PubMed ID: 18459457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
    Perner S; Hofer MD; Kim R; Shah RB; Li H; Möller P; Hautmann RE; Gschwend JE; Kuefer R; Rubin MA
    Hum Pathol; 2007 May; 38(5):696-701. PubMed ID: 17320151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
    Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
    Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival.
    Richmond PJ; Karayiannakis AJ; Nagafuchi A; Kaisary AV; Pignatelli M
    Cancer Res; 1997 Aug; 57(15):3189-93. PubMed ID: 9242448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone.
    Saha B; Arase A; Imam SS; Tsao-Wei D; Naritoku WY; Groshen S; Jones LW; Imam SA
    Prostate; 2008 Jan; 68(1):78-84. PubMed ID: 18008331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin.
    Song Y; Oda Y; Hori M; Kuroiwa K; Ono M; Hosoi F; Basaki Y; Tokunaga S; Kuwano M; Naito S; Tsuneyoshi M
    Hum Pathol; 2010 Feb; 41(2):214-22. PubMed ID: 19800102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
    Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
    Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unmethylated E-cadherin gene expression is significantly associated with metastatic human prostate cancer cells in bone.
    Saha B; Kaur P; Tsao-Wei D; Naritoku WY; Groshen S; Datar RH; Jones LW; Imam SA
    Prostate; 2008 Nov; 68(15):1681-8. PubMed ID: 18712716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis.
    Erdamar S; Yang G; Harper JW; Lu X; Kattan MW; Thompson TC; Wheeler TM
    Mod Pathol; 1999 Aug; 12(8):751-5. PubMed ID: 10463475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression.
    Mucci NR; Akdas G; Manely S; Rubin MA
    Hum Pathol; 2000 Apr; 31(4):406-14. PubMed ID: 10821485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
    Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
    J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.